1:46PM Introgen announces INGN 241 works synergistically with Avastin to cut blood supply to cancers (INGN) 4.57 +0.28 : Co reported data from preclinical studies in which mda-7, the active component of INGN 241, in combination with Avastin (DNA), produced a complete and synergistic therapeutic effect in models of lung cancer. INGN 241 and Avastin each inhibit the development of blood vessels in tumors, called angiogenesis, through distinct mechanisms, and the combination of the two agents significantly increases antitumor activity compared to the activity of either agent used alone. "These results are very encouraging because they suggest that the anti- cancer activity of targeted, anti-angiogenic agents can be enhanced without increasing toxicity,"
Market Data 
Markets 
AI
